QGel wins two Global Innovation Awards

On April 8, 2019, QGel was selected as a Finalist in the Health and Wellness category as part of Fast Company 2019 World Changing Ideas Awards. World Changing Ideas is one of Fast Company’s major annual awards programs and is focused on social good, seeking to elevate finished products and brave concepts that make the world better. A panel of judges from across sectors choose winners, finalists, and honorable mentions based on feasibility and the potential for impact. With a goal of awarding ingenuity and fostering innovation, Fast Company draws attention to ideas with great potential and helps them expand their reach to inspire more people to start working on solving the problems that affect us all.

QGel has also been awarded as Gold Medal Winner at the Edison Awards on April 4, 2019. Since 1987, the Edison Awards have recognized and honored some of the most innovative new products, services and business leaders in the world. The Edison Best New Product Awards is an annual competition honoring excellence in new product and service development, marketing, human-centered design, and innovation. The Edison Awards are focused on the innovators as much as the innovations. Award winners represent “game changing” products and services, as well as excellence and leadership in innovation around four criteria: Concept, Value, Delivery, and Impact. QGel won the Gold Medal in the Medical and Cancer Therapy category. The ballot of nominees for the Edison Awards was judged by a panel of more than 3,000 leading business executives including past award winners, academics and leaders in the fields of product development, design, engineering, science and medical.

These are the second and third global recognitions for QGel technology in the past year.

Leveraging innovation in next-generation drug discovery 

QGel’s technology gives scientists greater visibility into drug efficacy before the clinical trial phase by enabling them to carry out in vitro tests on cell cultures under in vivo conditions (i.e., conditions within the human body). With this better understanding of the potential of each new drug under development, they can focus their efforts on the most promising ones and get them in the hands of patients faster. The company’s technology also has encouraging applications in diagnostics, where it can be used to test drug efficacy directly on patients’ cancer cells after a biopsy – thus shortening the time it takes to find the right treatment for a given disease.